Arkolith/Insider Trading/APLS/Form 4

Meltzer Leslie

Chief Research and DevelopmentApellis Pharmaceuticals, Inc. (APLS) · full profile →Form 4 · filed May 14, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
7 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 14, 2026Tender(U)107K——0
May 14, 2026Grant(A)23K——23K
May 14, 2026Disposed to issuer(D)23K——0
May 14, 2026Grant(A)45K——45K
May 14, 2026Disposed to issuer(D)45K——0
May 14, 2026Disposed to issuer(D)62K——0
May 14, 2026Disposed to issuer(D)45K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 14, 2026Disposed to issuer(D)93K——0

Transaction Codes

U
See SEC Form 4 code table
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-224620) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML